News

At present, deployed members of the military are not permitted to be receiving therapy with systemic therapies such as immunomodulators and biologics.

Posters from the Academy of Managed Care Pharmacy annual meeting featured studies on atopic dermatitis.

Sixty percent of dupilumab-treated patients with AD treated with 400mg of eblasakimab weekly achieved EASI-90 after 16 weeks.

Chinese clinical researchers recently presented a unique case of JLIS manifesting as erythematous papules and infiltrative plaques on the nose and upper jaw, resembling rosacea.

In vitro studies demonstrated that retinoic acid aids stem cells in transitioning away from a state of flexibility in wound healing.

The CRL indicates that the timing proposed for data submission would not allow enough time for the FDA to complete its review by the May 25 PDUFA date.

LC-OCT provided quick, noninvasive assessment of skin conditions with detailed imaging aids diagnosis and treatment, especially for patients with darker skin types.

Hasbargen presented Mohs surgery pearls on closure types and pattern recognition at the 2024 Diversity in Dermatology meeting.

This Earth Day, we are reviewing studies and research linking the role of the environment with various skin conditions.

Click here to read more and answer our quiz questions in recognition of Rosacea Awareness Month.

The European approval was based on data from the Phase III BE HEARD I and BE HEARD II trials.

Last week, the US Food and Drug Administration approved biosimilar ustekinumab-aekn (Selarsdi; Alvotech and Teva) for psoriasis and PsA.

Keep up with the latest headlines in dermatology from the past week, including health alerts and warnings of counterfeit Botox in several states, Washington state's first clinic with radiation therapy for nonmelanoma skin cancer, and more

ICYMI, this week we had news about partnering with Spherix Global Insights, a look back at the rosacea pipeline, what dermatology clinicians need to know about recent counterfeit Botox, and more.

Blackburn presented integrative medicine pearls on gut and hormone health at the 2024 Diversity in Dermatology meeting.

A recent review and meta-analysis says this statistic may be due in part to nocebo effects.

Earlier this week, we shared our second Rosacea Awareness Month quiz. Review the answers and your responses below.

Researchers examined local skin reactions of a topical gel inhibiting cytosolic phospholipase A2 both in-clinic and remotely.

Scurto presented integrative medicine pearls at the 2024 Diversity in Dermatology meeting.

Noor, the co-owner of Rao Dermatology, shares about his interests in dermatology and what he most looks forward to as a member of our board.

Researchers noted that further examination and monitoring for headache disorders in patients with atopic dermatitis may be warranted.

Researchers compared a variable-sequenced, large-spot 532 nm KTP laser to the 595 nm pulsed-dye laser.

Data stems from week 28 results of the German G-EPOSS study evaluating the effectiveness of guselkumab in skin health, quality of life, sexuality, and stigmatization.

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

In this week’s Pointers With Portela, the 208SkinDoc discusses the effectiveness of a minimalist anti-aging skin care routine for patients.

Researchers recently developed and validated the 3-question social comparison scale, which may be applicable outside of conditions such as eczema and psoriasis.

Addressing gender inequity in academic dermatology involves strengthening societies, celebrating female dermatologists, promoting leadership, and equitable representation, authors wrote.

The WHO underscores the significance of addressing scabies as a neglected skin disease, especially in regions with limited health care access.

A study demonstrated the favorable efficacy and safety profiles of secukinumab in patients with severe HS for up to 52 weeks.

Interim findings from the PROSPER study of mogamulizumab in adults with CTCL were recently presented orally.